Skip to main content
TipRanks
Go Ultimate75% OFF

CVS Health Corporation Shs Sponsored Canadian Depositary Receipt Repr Sh (CVS) Q3 2026 Earnings Report

3 Followers

TSE:CVS Q3 2026 EPS Results

Actual EPS
CAD 2.36
Consensus EPS
―
Beat/Miss
―
One Year Ago EPS
-CAD 4.31

TSE:CVS Q3 2026 Revenue Results

Actual Revenue
CAD 151.75B
Expected Revenue
―
Beat/Miss
―
YoY Revenue Growth
+7.11%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/04/2026
Time
Before Open
Conference Call
Wednesday, November 4, 2026
TSE:CVS Upcoming Earnings

CVS Health Corporation Shs Sponsored Canadian Depositary Receipt Repr Sh's next earnings date is estimated for February 17, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

No earnings call audio is available for this earnings event.

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 04, 2026|% Change Since:-11.15%|
Earnings Call Sentiment|Positive

The call was strongly positive overall. CVS reported broad-based third-quarter earnings growth, raised 2026 earnings, revenue and cash flow guidance, achieved its leverage goal ahead of schedule, and expects continued earnings and margin improvement through 2027 and 2028. The company also announced a strategic separation from a position management described as strong. Key challenges include elevated medical cost trends, an expected 340B decline, health plan membership attrition, a less robust selling season, consumer dynamics and one-time separation costs, but management characterized these issues as understood, manageable or transitory.

Company Guidance

For 2026, CVS Health raised adjusted EPS guidance to at least $8.20, from the prior range of $7.90 to $8.10, expects total revenues of at least $420 billion, Healthcare Benefits adjusted operating income of at least $5.4 billion, MBR in the lower half of our previously discussed range of 89.75% plus or minus 25-basis-points, Pharmacy and Consumer Wellness adjusted operating income of $6.5 billion, nearly 8% growth from the prior year, enterprise adjusted operating income of at least $17.05 billion, and cash flow from operations of at least $15.5 billion; for 2027, it expects Healthcare Benefits another year of meaningful margin improvement, Health Services adjusted operating income of at least $7 billion, Pharmacy and Consumer Wellness adjusted operating income to grow low single digits off our current 2026 guidance of $6.5 billion, adjusted EPS of at least $8.65, approximately 13% growth off an adjusted 2026 baseline, trough earnings for the Health Services segment, and to return to growth from there; through 2028, it expects to be in the high end of our mid-teens adjusted EPS CAGR.

  • Planned Separation into Two Public CompaniesCVS Health announced its intention to separate into two independent publicly traded companies: a healthcare solutions company retaining Aetna, Caremark and Pharmacy Services, Specialty Pharmacy, Oak Street and Signify Health, and CVS Pharmacy, comprising retail pharmacy stores, mail order, MinuteClinic and Health 100. The transaction is expected to be tax-free for U.S. federal income tax purposes and completed in the first half of 2028, subject to customary conditions.
  • Strong Third-Quarter Financial ResultsCVS Health generated over $108 billion of revenue, nearly $4.2 billion of adjusted operating income and adjusted EPS of $2.09 in the third quarter. Adjusted EPS increased by over 30% from the prior-year quarter, with earnings growth across all operating segments.
  • Raised Full-Year 2026 Earnings and Cash Flow GuidanceFull-year 2026 adjusted EPS guidance was raised to at least $8.20 from the prior range of $7.90 to $8.10. Cash flow from operations guidance was increased to at least $15.5 billion. The updated adjusted EPS outlook is now more than $1 above initial 2026 expectations, while cash flow guidance has increased by more than $5.5 billion for the year.
  • Higher 2026 Revenue and Operating Income OutlookCVS now expects full-year 2026 total revenue of at least $420 billion and enterprise adjusted operating income of at least $17.05 billion. Healthcare Benefits adjusted operating income guidance was raised by $200 million to at least $5.4 billion, while Pharmacy and Consumer Wellness adjusted operating income guidance was raised by $100 million to $6.5 billion, representing nearly 8% growth from the prior year.
  • Healthcare Benefits Margin RecoveryHealthcare Benefits delivered third-quarter adjusted operating income of $900 million, an increase of nearly $600 million from the prior-year quarter. The medical benefit ratio was 91.3%, an improvement of approximately 150 basis points, primarily driven by improved underlying performance in Medicare. Full-year medical benefit ratio guidance was updated to the lower half of the previously discussed range of 89.75% plus or minus 25 basis points.
  • Medicare Business Exceeded ExpectationsMedicare performance modestly exceeded expectations, driven by pockets of favorability resulting from strong medical cost management and disciplined pricing. Management said the Medicare business is moving into profitable territory in 2026, with approximately 75% of the group Medicare Advantage book expected to be repriced by 2027.
  • Health Services Delivered Growth and Maintained ExpectationsHealth Services generated $2.1 billion of adjusted operating income in the quarter, an increase of nearly 3% from the prior-year quarter. The result was primarily driven by improved purchasing economics and pharmacy drug mix, partially offset by continued pharmacy client price improvements. Pharmacy Services, including the 340B business and rebate guarantees, and healthcare delivery performed in line with expectations.
  • Pharmacy and Consumer Wellness StrengthPharmacy and Consumer Wellness delivered over $1.6 billion of adjusted operating income, an increase of over 10% from the prior-year quarter. The result was primarily driven by core pharmacy strength, including a nearly 4% increase in same-store prescription volumes.
  • Retail Prescription and GLP-1 Volume GrowthCompensated prescription volumes grew 3.9% in the quarter, while GLP-1 prescriptions grew 23%. Management attributed the GLP-1 performance to actions that made access more affordable and easier for patients.
  • Balance Sheet Progress and Capital Deployment CapacityCVS generated approximately $4.7 billion of cash flow from operations in the quarter and $15.3 billion year to date. The company ended the quarter with $6 billion of cash at the parent and unrestricted subsidiaries, achieved its leverage goal ahead of schedule, and returned $2.6 billion to shareholders through dividends year to date. Management expects to resume share repurchases in the fourth quarter.
  • Positive 2027 Earnings OutlookCVS expects at least $8.65 of adjusted EPS in 2027, representing approximately 13% growth from an adjusted 2026 baseline. The outlook assumes the offset of dilution through share repurchases. Management also expects to be at the high end of its mid-teens adjusted EPS CAGR through 2028.
  • 2027 Segment Growth ExpectationsHealthcare Benefits is expected to deliver another year of meaningful margin improvement. Health Services is expected to generate at least $7 billion of adjusted operating income in 2027, with continued strength in specialty and another year of improvement in healthcare delivery. Pharmacy and Consumer Wellness adjusted operating income is expected to grow low single digits from the current 2026 guidance of $6.5 billion.
  • Expected Health Services Stabilization and Return to GrowthManagement expects the 340B business to largely stabilize by the end of 2027, views 2027 as trough earnings for Health Services, and expects the segment to return to growth thereafter. Management also expressed confidence entering the 2028 PBM selling season and said the new-business pipeline is expected to be robust.
  • Retail Technology and Workforce InvestmentsAI now supports pharmacy workflow for 85% of prescriptions. CVS also highlighted investments supporting approximately 30,000 pharmacists and 200,000 store colleagues, as well as efforts to improve customer experience and omnichannel capabilities.
  • Health 100 and Technology StrategyCVS continues to invest in Health 100, described as an AI-native integrated healthcare engagement platform and the front door of health and care. Management said the separation is expected to accelerate Health 100 adoption and development, improve connectivity, and support innovation across both companies.
  • Specialty Pharmacy and Integrated Care PositioningCVS plans to retain Specialty Pharmacy within CVS Health to address affordability and access, manage rising specialty drug costs, and serve high-acuity populations. Management stated that 2% of the population drives more than 50% of pharmacy spending and that specialty pharmacy continues to be a major driver of customer cost trends.
  • Strong Positioning of the Two Future BusinessesManagement said both future companies are expected to have solid investment-grade balance sheets and strong free cash flow generation. CVS Health is positioned across a more than $2 trillion growing market, while CVS Pharmacy is positioned in a greater than $500 billion market with 9,000 stores and opportunities to expand community-based healthcare services.
  • Commercial Agreements to Preserve Key CapabilitiesManagement said products and capabilities developed between CVS Pharmacy and Caremark will be preserved through commercial agreements. Health 100 is expected to serve as connective tissue between the companies, with CVS Pharmacy providing consumer engagement and Aetna and Caremark contributing financial and healthcare information.

TSE:CVS Earnings History

TSE:CVS earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 17, 20272026 (Q4)―-3.21――
Nov 04, 20262026 (Q3)―2.35-4.31154.59% (+6.67)
Aug 05, 20262026 (Q2)―3.201.11187.87% (+2.09)
May 06, 20262026 (Q1)―3.162.0256.32% (+1.14)
Feb 18, 20262025 (Q4)―3.211.8276.30% (+1.39)
Oct 29, 20252025 (Q3)―-4.310.09-4689.36% (-4.41)
Jul 31, 20252025 (Q2)―1.111.92-42.15% (-0.81)
May 01, 20252025 (Q1)―2.021.1970.38% (+0.83)
Feb 12, 20252024 (Q4)―1.822.15-15.41% (-0.33)
Nov 06, 20242024 (Q3)―0.092.35-96.00% (-2.26)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed